Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study.
COVID-19
EMS
emergency medical services
medical services
naloxone
opioid crisis
opioids
outcomes
overdose
pandemic
public health
Journal
JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345
Informations de publication
Date de publication:
27 05 2021
27 05 2021
Historique:
received:
01
04
2021
accepted:
10
05
2021
revised:
06
05
2021
pubmed:
18
5
2021
medline:
4
6
2021
entrez:
17
5
2021
Statut:
epublish
Résumé
The opioid crisis in the United States may be exacerbated by the COVID-19 pandemic. Increases in opioid use, emergency medical services (EMS) runs for opioid-related overdoses, and opioid overdose deaths have been reported. No study has examined changes in multiple naloxone administrations, an indicator of overdose severity, during the COVID-19 pandemic. This study examines changes in the occurrence of naloxone administrations and multiple naloxone administrations during EMS runs for opioid-related overdoses during the COVID-19 pandemic in Guilford County, North Carolina (NC). Using a period-over-period approach, we compared the occurrence of opioid-related EMS runs, naloxone administrations, and multiple naloxone administrations during the 29-week period before (September 1, 2019, to March 9, 2020) and after NC's COVID-19 state of emergency declaration (ie, the COVID-19 period of March 10 to September 30, 2020). Furthermore, historical data were used to generate a quasi-control distribution of period-over-period changes to compare the occurrence of each outcome during the COVID-19 period to each 29-week period back to January 1, 2014. All outcomes increased during the COVID-19 period. Compared to the previous 29 weeks, the COVID-19 period experienced increases in the weekly mean number of opioid-related EMS runs (25.6, SD 5.6 vs 18.6, SD 6.6; P<.001), naloxone administrations (22.3, SD 6.2 vs 14.1, SD 6.0; P<.001), and multiple naloxone administrations (5.0, SD 1.9 vs 2.7, SD 1.9; P<.001), corresponding to proportional increases of 37.4%, 57.8%, and 84.8%, respectively. Additionally, the increases during the COVID-19 period were greater than 91% of all historical 29-week periods analyzed. The occurrence of EMS runs for opioid-related overdoses, naloxone administrations, and multiple naloxone administrations during EMS runs increased during the COVID-19 pandemic in Guilford County, NC. For a host of reasons that need to be explored, the COVID-19 pandemic appears to have exacerbated the opioid crisis.
Sections du résumé
BACKGROUND
The opioid crisis in the United States may be exacerbated by the COVID-19 pandemic. Increases in opioid use, emergency medical services (EMS) runs for opioid-related overdoses, and opioid overdose deaths have been reported. No study has examined changes in multiple naloxone administrations, an indicator of overdose severity, during the COVID-19 pandemic.
OBJECTIVE
This study examines changes in the occurrence of naloxone administrations and multiple naloxone administrations during EMS runs for opioid-related overdoses during the COVID-19 pandemic in Guilford County, North Carolina (NC).
METHODS
Using a period-over-period approach, we compared the occurrence of opioid-related EMS runs, naloxone administrations, and multiple naloxone administrations during the 29-week period before (September 1, 2019, to March 9, 2020) and after NC's COVID-19 state of emergency declaration (ie, the COVID-19 period of March 10 to September 30, 2020). Furthermore, historical data were used to generate a quasi-control distribution of period-over-period changes to compare the occurrence of each outcome during the COVID-19 period to each 29-week period back to January 1, 2014.
RESULTS
All outcomes increased during the COVID-19 period. Compared to the previous 29 weeks, the COVID-19 period experienced increases in the weekly mean number of opioid-related EMS runs (25.6, SD 5.6 vs 18.6, SD 6.6; P<.001), naloxone administrations (22.3, SD 6.2 vs 14.1, SD 6.0; P<.001), and multiple naloxone administrations (5.0, SD 1.9 vs 2.7, SD 1.9; P<.001), corresponding to proportional increases of 37.4%, 57.8%, and 84.8%, respectively. Additionally, the increases during the COVID-19 period were greater than 91% of all historical 29-week periods analyzed.
CONCLUSIONS
The occurrence of EMS runs for opioid-related overdoses, naloxone administrations, and multiple naloxone administrations during EMS runs increased during the COVID-19 pandemic in Guilford County, NC. For a host of reasons that need to be explored, the COVID-19 pandemic appears to have exacerbated the opioid crisis.
Identifiants
pubmed: 33999828
pii: v7i5e29298
doi: 10.2196/29298
pmc: PMC8163496
doi:
Substances chimiques
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29298Subventions
Organisme : Intramural NIH HHS
ID : ZIA MH002953
Pays : United States
Informations de copyright
©Dalia Khoury, Alexander Preiss, Paul Geiger, Mohd Anwar, Kevin Paul Conway. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 27.05.2021.
Références
JMIR Public Health Surveill. 2020 Jun 24;6(2):e17574
pubmed: 32469322
Acad Emerg Med. 2020 Aug;27(8):693-699
pubmed: 32557999
Drug Alcohol Depend. 2020 Nov 1;216:108321
pubmed: 33007700
Nat Med. 2020 Jun;26(6):819-820
pubmed: 32555514
J Urban Health. 2020 Dec;97(6):802-807
pubmed: 33005988
Hum Genet. 2012 Jun;131(6):779-89
pubmed: 22543841
Annu Rev Public Health. 2018 Apr 1;39:453-469
pubmed: 29328877
MMWR Morb Mortal Wkly Rep. 2017 Apr 14;66(14):382-386
pubmed: 28406883
R I Med J (2013). 2019 Mar 1;102(2):41-45
pubmed: 30823701
Int J Drug Policy. 2019 Sep;71:183-188
pubmed: 30718120
Oncogene. 2002 Oct 21;21(48):7326-40
pubmed: 12379876
Prehosp Emerg Care. 2017 Nov-Dec;21(6):682-687
pubmed: 28686547
Ann N Y Acad Sci. 2019 Sep;1451(1):130-143
pubmed: 31378974
MMWR Morb Mortal Wkly Rep. 2020 Mar 13;69(10):271-273
pubmed: 32163382
Int J Drug Policy. 2020 Sep;83:102821
pubmed: 32591222
JAMA Psychiatry. 2021 May 1;78(5):562-564
pubmed: 33270086
Prehosp Emerg Care. 2017 Jul-Aug;21(4):411-419
pubmed: 28481656
Drug Alcohol Depend. 2020 Sep 1;214:108176
pubmed: 32717504
Drug Alcohol Rev. 2020 May;39(4):297-300
pubmed: 32445265
Int J Drug Policy. 2020 Sep;83:102896
pubmed: 32768156
Ann Intern Med. 2020 Jul 7;173(1):59-60
pubmed: 32240291
Dialogues Clin Neurosci. 2009;11(1):7-20
pubmed: 19432384
JAMA Psychiatry. 2020 Sep 1;:
pubmed: 32870241
MMWR Morb Mortal Wkly Rep. 2018 Aug 10;67(31):850-853
pubmed: 30091966
Am J Public Health. 2015 Jul;105 Suppl 3:e26-32
pubmed: 25905856
Ther Adv Drug Saf. 2018 Jan;9(1):63-88
pubmed: 29318006
JAMA Netw Open. 2019 Nov 1;2(11):e1914666
pubmed: 31702795
AIDS Behav. 2020 Sep;24(9):2466-2468
pubmed: 32333209
Popul Health Manag. 2021 Feb;24(S1):S43-S51
pubmed: 33031013
N Engl J Med. 2007 Jan 11;356(2):157-65
pubmed: 17215533
JAMA. 2020 Oct 27;324(16):1674-1677
pubmed: 32945855
JAMA Netw Open. 2021 Apr 1;4(4):e217112
pubmed: 33852004
JAMA. 2021 Feb 9;325(6):523
pubmed: 33560330
Addiction. 2018 Dec;113(12):2271-2279
pubmed: 30255531
Ann Intern Med. 2020 Jul 7;173(1):57-58
pubmed: 32240283
Mol Psychiatry. 2021 Jan;26(1):41-50
pubmed: 33188253
Am J Emerg Med. 2017 Nov;35(11):1706-1708
pubmed: 28506507
Am J Public Health. 2018 Feb;108(2):182-186
pubmed: 29267060
Prehosp Emerg Care. 2013 Jul-Sep;17(3):317-29
pubmed: 23734988
Prehosp Disaster Med. 2015 Aug;30(4):385-9
pubmed: 26061280